Science Translational Medicine Impact Factor

Data sourced from our analysis of 20,449 journals in the Clarivate JCR 2024 database.

The important pattern here is not whether the number moved a little up or down in one cycle. It is that Science Translational Medicine stays in the group of journals that translational researchers treat as a serious destination rather than a fallback. The journal has a stable role in the bench-to-bedside part of biomedicine, where strong disease models, human validation, and therapeutic relevance meet.

That gives the number a specific meaning. A 14.6 JIF here does not behave like 14.6 in every other field. It reflects a journal that sits between basic mechanism and direct clinical practice, where papers are expected to matter beyond one experimental technique but still stay grounded in real disease biology.

In practical terms, the trend says the journal remains a high-bar translational venue. Authors should read the number as evidence of durable influence inside translational biomedicine, not as a shortcut to "good enough for any paper with patient relevance."

That nuance matters because translational medicine is crowded with papers that look promising at first glance. Science Translational Medicine does not simply reward disease relevance as a theme. It rewards papers where the bridge from mechanism to application feels convincing enough that both sides of the audience can take the result seriously.

It gives you a useful signal about how the journal is positioned.

• Science Translational Medicine is a recognized destination for work that links mechanistic insight to disease relevance.
• The journal has enough citation density that publication here carries meaningful visibility in translational circles.
• Readers expect papers to matter to both laboratory researchers and clinically minded audiences.
• The journal's influence is strong enough that authors often compare it with other ambitious translational targets rather than with routine specialist outlets.

That is the upside of the number. It confirms that this is a serious translational journal with real reach.

• whether your manuscript actually fits the journal
• how likely the editor is to desk reject
• how long peer review will take
• how your specific paper will perform after publication

Those missing pieces matter more than usual in translational medicine. A paper can have beautiful mechanistic work and still miss the journal if the bridge to disease significance feels thin. A paper can have interesting patient data and still miss if the mechanistic logic feels underbuilt. The JIF does not resolve either problem.

If you are genuinely deciding whether to submit here, focus on the translational architecture of the manuscript.

• Is there a clear bridge from biological mechanism to disease relevance?
• Does the paper go beyond a promising model and show why the result matters for human health?
• Are the claims grounded in evidence that feels reviewable by both mechanistic and translational readers?
• Does the manuscript feel like a translational story from the beginning, rather than a basic paper with a thin clinical paragraph attached at the end?

That is usually a better prediction of outcome than the metric itself. The Science Translational Medicine journal profile is more useful than the raw number if you are trying to judge the editorial bar.

The most common mistake is reading 14.6 as a generic prestige label instead of a translational filter.

Some authors treat the number as proof that a strong mechanistic paper should aim here. That can be wrong if the human relevance is still too speculative. Others treat the number as lower than the giant general-medical titles and conclude the journal is more forgiving. That is also misleading. Science Translational Medicine can be less broad than those titles and still be highly selective because the paper has to satisfy a very specific translational standard.

In other words, the number helps you place the journal. It does not replace judgment about manuscript shape.

The cleanest interpretation is this:

• too high to treat as a routine backup journal
• too specialized to evaluate like a general-medical trophy target
• strongest for papers that connect mechanism, disease biology, and practical therapeutic or diagnostic relevance

If your manuscript mainly shines because of elegant basic biology, a different journal may judge it more naturally. If it mainly shines because of clinical utility without enough mechanistic depth, that can also be a mismatch. Science Translational Medicine works best when the bridge is the story.

That is the practical value of the metric page. It helps you place the journal correctly in the market, then pushes you toward the harder but more important question: does your manuscript genuinely read like translational medicine, or does it only hope to be interpreted that way?

In our pre-submission review work on manuscripts targeting Science Translational Medicine, three patterns account for most of the desk rejections we see.

Basic science papers with translational language added in the discussion. STM's editorial identity is genuinely translational, papers need to demonstrate a mechanistic advance and a credible path toward clinical application, not just claim relevance to disease in the conclusion. We see manuscripts from basic research labs that have generated strong mechanistic data, added a section framing the findings as "relevant to drug development" or "suggesting therapeutic potential," and targeted STM. The AAAS professional editors read through that framing immediately. The translational connection needs to be in the experimental logic: human data or human-relevant model systems, pharmacological evidence, or a direct link to a clinical trial or therapeutic hypothesis. Without those, the paper belongs in Cell, Molecular Cell, or a field-specific research journal.

Human relevance claimed through mouse models alone. STM has a specific relationship with animal models: they are acceptable as part of a translational package, but they are not sufficient on their own to establish translational relevance. We see papers that generate compelling mouse model data for a therapeutic intervention (knockouts, drug treatments, disease models) and submit to STM because the finding "has implications for human disease." STM editors want human data alongside or framing the animal work. This can be retrospective patient samples, human cell lines or organoids, genetic data from human cohorts, or primary patient-derived material. The mouse data should answer a mechanistic question that the human data has already raised, not substitute for it.

Papers where the clinical hypothesis is speculative rather than grounded. The strongest STM papers present a therapeutic, diagnostic, or preventive hypothesis that the data directly tests or substantiates. We see submissions where the clinical connection is genuinely interesting but entirely speculative ("this pathway could potentially be targeted for therapy") without any pharmacological, genetic, or clinical evidence that the connection is feasible. STM editors are trained in translational medicine. Speculative clinical framing in a paper otherwise about basic biology reads as wishful rather than translational. The bar is not "might be relevant" but "here is evidence that this is relevant and testable."

Submit if:

• Your paper bridges molecular or cellular mechanisms to human disease with a clear therapeutic, diagnostic, or preventive path
• The translational architecture is convincing to both mechanistic and clinically minded reviewers, not just one side
• The manuscript reads as a translational story from the beginning, with the bench-to-bedside bridge built into the design rather than tacked on
• You want an AAAS-family venue (IF 14.6, ~5-8% acceptance) specifically positioned for work that connects mechanism to clinical relevance

Think twice if:

• The paper is elegant basic biology without a convincing bridge to disease significance or human health relevance
• The clinical utility is strong but the mechanistic depth is underbuilt, since STM requires both sides of the translational story
• The work is better described as a clinical study without mechanistic novelty, which fits better at a general-medical journal like NEJM or JAMA
• Nature Medicine (IF 50.0) is a realistic target for the same paper, since it is broader and higher prestige for translational work

The headline IF of 14.6 is just the starting point. The full JCR profile tells you more about how STM papers actually perform in the citation ecosystem.

STM ranks 3rd out of 195 journals in the Medicine, Research & Experimental category. That's behind Nature Medicine (IF 50.0, rank 1) and ahead of JCI (IF 13.6, rank 5). The 5-year IF of 16.0 shows citation accumulation stays strong beyond the initial two-year window. The JIF Without Self-Cites of 14.5 confirms the journal isn't inflating its numbers, self-citation accounts for less than 1% of the total.

The Cited Half-Life of 6.5 years is worth noting. STM papers keep getting cited for over half a decade, which is strong for a translational venue where methods and therapeutic targets evolve quickly. Total cites of 52,583 across 266 articles per year means each paper enters a well-cited ecosystem.

The practical takeaway: STM is solidly in the top tier of translational medicine journals. It's not Nature Medicine, but it's not trying to be. If your work fits the translational niche, STM gives you Q1 visibility with a focused readership that actually works in the bench-to-bedside space.

STM occupies a specific lane that's different from every other high-IF translational journal. Understanding that lane is the difference between a strong submission and a desk rejection.

Nature Medicine publishes broadly across translational and clinical research, it'll take a pure clinical study or a pure disease mechanism paper if the impact is high enough. JCI leans toward disease mechanisms with pathophysiological insight. Science Advances covers translational work but without the clinical focus. STM's sweet spot is narrower: the paper where the translational step itself is the contribution.

That means STM wants to see work where moving from bench to bedside isn't background context, it's the story. The ideal STM paper starts with a molecular or cellular finding, validates it in human tissue or patient samples, and points toward a specific therapeutic, diagnostic, or preventive application. Both sides of the bridge need to be load-bearing.

If you're unsure which of these journals fits your translational manuscript, a STM translational framing check can assess the fit before you commit to a submission.

STM's acceptance rate of 5-8% means editors are filtering hard. Knowing what succeeds and what doesn't saves you months of misrouted submissions.

The papers that succeed at STM share a pattern: they don't just show something works, they show why it works in a way that matters for patients. First-in-human studies with pharmacokinetic and pharmacodynamic data do well. Biomarker discovery papers succeed when they include clinical validation in patient cohorts, not just discovery in cell lines. Drug repurposing studies need a mechanistic explanation for why the drug works in the new indication, "we screened 2,000 compounds and found one that works" isn't enough without the biology.

The rejection patterns are equally instructive. Pure clinical studies without mechanistic depth belong at general medical journals. Animal-only studies without human validation feel premature for STM. And papers where the "translational" component is a single paragraph in the Discussion speculating about clinical potential don't clear the bar, STM editors can spot bolted-on translational framing immediately.

• Science Translational Medicine journal profile and author guidance
• Science Translational Medicine - For Authors
• Science Translational Medicine - Journal